ArticleMolecular and clinical oncology2025
Real‑world application of Cytalux for targeted imaging of occult peritoneal disease in epithelial ovarian cancer.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult disease in normal-appearing peritoneum is common in epithelial ovarian cancer (EOC), especially after neoadjuvant chemotherapy (NACT). Pafolacianine (Cytalux) is the first Food and Drug Administration-approved agent for targeted imaging of EOC occult disease. The current study presents its first out-of-trial use during cytoreductive surgery (CRS). This study analyzed three cases of Cytalux application in patients with EOC and peritoneal metastases who underwent CRS and hyperthermic intraperitoneal chemoperfusion. Targeted imaging with Cytalux was performed before CRS to confirm uptake by visible lesions and after to identify occult disease. The association between Cytalux-positive disease and pathology was evaluated. Patient A had primary EOC and patients B and C had recurrent disease. All patients received NACT. Patient A had a peritoneal cancer index (PCI) of 21 and a completeness of cytoreduction (CC) score of 1, while patients B and C both had PCI 9 and CC score of 0. Cytalux imaging was associated with all macroscopic lesions. In patient A, Cytalux identified 16 additional peritoneal lesions with 14 confirmed as metastases [true positive (TP) rate, 87.5%]. Two Cytalux-positive peritoneal areas were fulgurated until the signal loss but subsequently tested positive for cancer. In patients B and C, Cytalux detected two lesions in each case with 50.0% positive on pathology. Overall peritoneal-level TP and false positive (FP) rates were 80.0 and 20.0%, respectively. Cytalux can help identify occult EOC peritoneal disease and manage questionable areas of post-chemotherapy fibrosis. However, the FP rate is considerable. Cytalux signal navigation should not be used for energy destruction of lesions until more data are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.